UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000035938
Receipt number R000040936
Scientific Title Epidemiologic survey about zoster-associated pain and PHN in herpes zoster patients after antiherpesvirus drug treatment.
Date of disclosure of the study information 2019/02/19
Last modified on 2022/06/22 17:29:31

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Epidemiologic survey about zoster-associated pain and PHN in herpes zoster patients after antiherpesvirus drug treatment.

Acronym

pain residual rate survey

Scientific Title

Epidemiologic survey about zoster-associated pain and PHN in herpes zoster patients after antiherpesvirus drug treatment.

Scientific Title:Acronym

pain residual rate survey

Region

Japan


Condition

Condition

herpes zoster

Classification by specialty

Dermatology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The purpose is to investigate the herpes zoster-associated pain and PHN residual rate in the patients who was prescribed amenamevir Tab for herpes zoster, using an evaluation of the initial pain and a convalescence questionnaire.

Basic objectives2

Others

Basic objectives -Others

Observational

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Until disappearance of zoster-associated pain pass, and change time for 12M.

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

75 years-old >=

Gender

Male and Female

Key inclusion criteria

1) The patient of herpes zoster, and was prescribed amenamevir Tab.
2) Written informed consent
3) Age >=20 at informed consent

Key exclusion criteria

The patient who has the complications that cannot judge a pain due to the herpes zoster exactly.(For example, dementia, lumbago, others)

Target sample size

1000


Research contact person

Name of lead principal investigator

1st name Makoto
Middle name
Last name Kawashima

Organization

Non-Profit Organization
Health Institute Research of Skin

Division name

vice chief director

Zip code

101-0047

Address

FukudaBilding 2F,1-8-9 Uchikanda, Chiyoda-ku, Tokyo

TEL

03-3256-2575

Email

kawashima.makoto@twmu.ac.jp


Public contact

Name of contact person

1st name Yoshitaka
Middle name
Last name Ogaki

Organization

EBC&M LLC.

Division name

Clinical Business Department

Zip code

105-0011

Address

2-9-1 Shibakoen Minato-ku, Tokyo

TEL

03-6435-3833

Homepage URL


Email

yoshitaka_ogaki@ebc-m.com


Sponsor or person

Institute

Non-Profit Organization
Health Institute Research of Skin

Institute

Department

Personal name



Funding Source

Organization

Maruho Co.,Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Non-Profit Organization Health Institute Research of Skin Ethics Review Board

Address

FukudaBilding 2F,1-8-9 Uchikanda, Chiyoda-ku, Tokyo

Tel

0332562575

Email

info@npo-hifu.net


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 02 Month 19 Day


Related information

URL releasing protocol


Publication of results

Partially published


Result

URL related to results and publications


Number of participants that the trial has enrolled

1021

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2019 Year 01 Month 25 Day

Date of IRB

2019 Year 02 Month 15 Day

Anticipated trial start date

2019 Year 02 Month 26 Day

Last follow-up date

2020 Year 10 Month 31 Day

Date of closure to data entry

2020 Year 12 Month 27 Day

Date trial data considered complete

2021 Year 04 Month 20 Day

Date analysis concluded

2021 Year 07 Month 25 Day


Other

Other related information

Questionary survey at-home for 12 months


Management information

Registered date

2019 Year 02 Month 19 Day

Last modified on

2022 Year 06 Month 22 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000040936


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name